Summary List Placement
It feels so dissonant — the good news about vaccines working at the same time as case counts are rising even higher, New York’s shutting down its schools, and states and cities are making the tough decisions to lock back down in the hopes of mitigating even further spread of the virus.
But that’s indeed where we find ourselves in November 2020. How’s everyone holding up? Has anyone restarted a hobby? My sourdough starter’s back from hibernation as part of the move, ready for a winter’s worth of baking.
Before I jump right in to this week in vaccine news (Should I change the name of this newsletter to Insider Vaccines?), a reminder to subscribe to this newsletter here. And pass it along to your friends who might also enjoy daily dispatches of healthcare news!
Moderna’s vaccine win
On Monday, Moderna said that its vaccine was successful in preventing COVID-19.
The news came a week after Pfizer and BioNTech also shared that their vaccine was effective.
After its initial analysis, Moderna found that its vaccine was 94.5% effective at preventing COVID-19. As an added bonus: Moderna’s shots don’t need to be kept at super cold temperatures, unlike Pfizer’s version.
Andrew Dunn talked to Moderna’s CEO, who shared that he expects every American will likely have access to a COVID-19 vaccination by June.
Pfizer, not to be outdone, on Wednesday announced an update to its vaccine results, finding that the shot in a final analysis was 95% effective (In its initial analysis of the data, Pfizer had said that the shot was more than 90% effective).
It was an optimistic week all around — Bill Gates on Tuesday said he predicts several more vaccines will also be highly effective. That’d be good news, as having more vaccines should help more people around the world get vaccinated.
But, of course, the vaccine frontrunners haven’t been approved yet. Pfizer and BioNTech on Friday morning said that they anticipate applying for an emergency use authorization later that day.
Last week, Andrew chatted with the FDA’s Dr. Peter Marks, who laid out why it will take weeks to vet a COVID-19 shot.
Marks, who’s in charge of evaluating the vaccines, said the hope is to build up public trust in the process.
And the shots don’t come without some side effects — Moderna noted Monday that about 10% of trial participants had fatigue so serious it interfered with their daily lives. Dr. Catherine Schuster-Bruce has the story on why experts think the benefits outweigh the side effects.
For a comprehensive recap on everything you need to know about Moderna’s vaccine, Andrew and I have you covered.
Read the full story here>>
Moderna’s coronavirus vaccine is effective at preventing COVID-19, joining Pfizer’s shot. Here’s what you need to know.
Amazon’s long-awaited pharmacy service is here
On Tuesday, Amazon made it official by launching Amazon Pharmacy, selling prescription medications and offering discount services for Prime members paying without insurance.
Pharmacy has been one of Amazon’s big bets in …read more
Source:: Business Insider